Ahmed, A. T., Frye, M. A., Rush, A., Bobo, W. V., Biernacka, J., Flavin, D. H., … Dunlop, B. W. (2017). SUBPHENOTYPES IN MAJOR DEPRESSIVE DISORDER TO BETTER CHARACTERIZE PHARMACOGENOMIC ANTIDEPRESSANT TREATMENT RESPONSE. In CLINICAL PHARMACOLOGY & THERAPEUTICS (Vol. 101, pp. S19–S20). Washington, DC: WILEY-BLACKWELL.

Ahmed, A. T., M. A. Frye, A. Rush, W. V. Bobo, J. Biernacka, D Hall Flavin, G. D. Jenkins, et al. “SUBPHENOTYPES IN MAJOR DEPRESSIVE DISORDER TO BETTER CHARACTERIZE PHARMACOGENOMIC ANTIDEPRESSANT TREATMENT RESPONSE.” In CLINICAL PHARMACOLOGY & THERAPEUTICS, 101:S19–20. WILEY-BLACKWELL, 2017.

Ahmed AT, Frye MA, Rush A, Bobo WV, Biernacka J, Flavin DH, et al. SUBPHENOTYPES IN MAJOR DEPRESSIVE DISORDER TO BETTER CHARACTERIZE PHARMACOGENOMIC ANTIDEPRESSANT TREATMENT RESPONSE. In: CLINICAL PHARMACOLOGY & THERAPEUTICS. WILEY-BLACKWELL; 2017. p. S19–20.

Ahmed, A. T., et al. “SUBPHENOTYPES IN MAJOR DEPRESSIVE DISORDER TO BETTER CHARACTERIZE PHARMACOGENOMIC ANTIDEPRESSANT TREATMENT RESPONSE.” CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 101, no. S1, WILEY-BLACKWELL, 2017, pp. S19–20.

Ahmed AT, Frye MA, Rush A, Bobo WV, Biernacka J, Flavin DH, Jenkins GD, Batzle A, Skime MK, Wang L, Craighead W, Mayberg HS, Weinshilboum RM, Kaddurah-Daouk RF, Dunlop BW. SUBPHENOTYPES IN MAJOR DEPRESSIVE DISORDER TO BETTER CHARACTERIZE PHARMACOGENOMIC ANTIDEPRESSANT TREATMENT RESPONSE. CLINICAL PHARMACOLOGY & THERAPEUTICS. WILEY-BLACKWELL; 2017. p. S19–S20.